Zevra Therapeutics (ZVRA) Competitors

$11.12 +0.07 (+0.63%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$11.42 +0.30 (+2.70%)

As of 07:39 AM Eastern

ZVRA vs. ARQT, IRON, RARE, VERA, and IMNM

Should you buy Zevra Therapeutics stock or one of its competitors? MarketBeat compares Zevra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zevra Therapeutics include Arcutis Biotherapeutics (ARQT), Disc Medicine (IRON), Ultragenyx Pharmaceutical (RARE), Vera Therapeutics (VERA), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry.

How does Zevra Therapeutics compare to Arcutis Biotherapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Zevra Therapeutics has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.17	$83.23M	$1.99	5.59
Arcutis Biotherapeutics	$376.07M	7.21	-$16.14M	-$0.03	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Arcutis Biotherapeutics' net margin of -0.57%. Zevra Therapeutics' return on equity of 51.49% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

35.0% of Zevra Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zevra Therapeutics presently has a consensus target price of $23.33, suggesting a potential upside of 109.83%. Arcutis Biotherapeutics has a consensus target price of $34.00, suggesting a potential upside of 56.75%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Zevra Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 23 articles in the media. Zevra Therapeutics' average media sentiment score of 0.46 beat Arcutis Biotherapeutics' score of 0.15 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zevra Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Summary

Zevra Therapeutics beats Arcutis Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Zevra Therapeutics compare to Disc Medicine?

Zevra Therapeutics (NASDAQ:ZVRA) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Zevra Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.17	$83.23M	$1.99	5.59
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Disc Medicine's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Disc Medicine	N/A	-36.94%	-33.88%

In the previous week, Zevra Therapeutics had 6 more articles in the media than Disc Medicine. MarketBeat recorded 23 mentions for Zevra Therapeutics and 17 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.49 beat Zevra Therapeutics' score of 0.46 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics presently has a consensus target price of $23.33, suggesting a potential upside of 109.83%. Disc Medicine has a consensus target price of $104.80, suggesting a potential upside of 49.65%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Zevra Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Zevra Therapeutics beats Disc Medicine on 10 of the 15 factors compared between the two stocks.

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Zevra Therapeutics (NASDAQ:ZVRA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Zevra Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.17	$83.23M	$1.99	5.59
Ultragenyx Pharmaceutical	$670M	3.89	-$575M	-$6.11	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Zevra Therapeutics' return on equity of 51.49% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Zevra Therapeutics had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 23 mentions for Zevra Therapeutics and 22 mentions for Ultragenyx Pharmaceutical. Zevra Therapeutics' average media sentiment score of 0.46 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics presently has a consensus target price of $23.33, suggesting a potential upside of 109.83%. Ultragenyx Pharmaceutical has a consensus target price of $60.41, suggesting a potential upside of 128.31%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Zevra Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Zevra Therapeutics beats Ultragenyx Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does Zevra Therapeutics compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Vera Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Zevra Therapeutics	$106.47M	6.17	$83.23M	$1.99	5.59

Vera Therapeutics currently has a consensus target price of $79.60, indicating a potential upside of 103.32%. Zevra Therapeutics has a consensus target price of $23.33, indicating a potential upside of 109.83%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Zevra Therapeutics has a net margin of 101.58% compared to Vera Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Zevra Therapeutics	101.58%	51.49%	28.86%

In the previous week, Zevra Therapeutics had 3 more articles in the media than Vera Therapeutics. MarketBeat recorded 23 mentions for Zevra Therapeutics and 20 mentions for Vera Therapeutics. Zevra Therapeutics' average media sentiment score of 0.46 beat Vera Therapeutics' score of 0.18 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zevra Therapeutics beats Vera Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Zevra Therapeutics compare to Immunome?

Zevra Therapeutics (NASDAQ:ZVRA) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Zevra Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Immunome has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.17	$83.23M	$1.99	5.59
Immunome	$6.94M	362.27	-$212.39M	-$2.42	N/A

Zevra Therapeutics currently has a consensus target price of $23.33, indicating a potential upside of 109.83%. Immunome has a consensus target price of $33.45, indicating a potential upside of 50.70%. Given Zevra Therapeutics' higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Immunome	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Zevra Therapeutics has a net margin of 101.58% compared to Immunome's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Immunome	N/A	-57.71%	-52.69%

In the previous week, Zevra Therapeutics had 11 more articles in the media than Immunome. MarketBeat recorded 23 mentions for Zevra Therapeutics and 12 mentions for Immunome. Immunome's average media sentiment score of 0.97 beat Zevra Therapeutics' score of 0.46 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zevra Therapeutics beats Immunome on 9 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVRA vs. The Competition

Export

Metric	Zevra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$653.22M	$3.04B	$6.30B	$12.28B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	5.59	18.86	21.03	25.58
Price / Sales	6.17	295.51	554.66	78.88
Price / Cash	11.68	56.53	42.94	55.34
Price / Book	3.20	4.35	9.78	6.66
Net Income	$83.23M	$72.19M	$3.55B	$333.63M
7 Day Performance	1.09%	-1.05%	-0.52%	-0.12%
1 Month Performance	13.59%	-0.02%	1.21%	3.93%
1 Year Performance	36.61%	46.31%	41.26%	36.07%

Zevra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVRA Zevra Therapeutics	4.0271 of 5 stars	$11.12 +0.6%	$23.33 +109.8%	+41.3%	$653.22M	$106.47M	5.59	20	Analyst Revision
ARQT Arcutis Biotherapeutics	3.1941 of 5 stars	$21.17 +2.5%	$34.00 +60.6%	+56.9%	$2.58B	$376.07M	N/A	150	Gap Down High Trading Volume
IRON Disc Medicine	2.3931 of 5 stars	$68.26 +1.1%	$104.80 +53.5%	+51.1%	$2.58B	N/A	N/A	30
RARE Ultragenyx Pharmaceutical	3.2547 of 5 stars	$26.12 0.0%	$60.41 +131.3%	-25.3%	$2.57B	$673M	N/A	1,371	Trending News Analyst Downgrade Analyst Revision
VERA Vera Therapeutics	3.3044 of 5 stars	$36.19 +0.9%	$79.60 +120.0%	+81.4%	$2.56B	N/A	N/A	40	Earnings Report Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVRA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. ARQT, IRON, RARE, VERA, and IMNM

How does Zevra Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Zevra Therapeutics compare to Disc Medicine?

Summary

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Zevra Therapeutics compare to Vera Therapeutics?

Summary

How does Zevra Therapeutics compare to Immunome?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. ARQT, IRON, RARE, VERA, and IMNM

How does Zevra Therapeutics compare to Arcutis Biotherapeutics?

Which has preferable valuation & earnings, ZVRA or ARQT?

Is ZVRA or ARQT more profitable?

Do institutionals and insiders hold more shares of ZVRA or ARQT?

Do analysts recommend ZVRA or ARQT?

Does the media favor ZVRA or ARQT?

Which has more volatility and risk, ZVRA or ARQT?

Summary

How does Zevra Therapeutics compare to Disc Medicine?

Which has better earnings & valuation, ZVRA or IRON?

Is ZVRA or IRON more profitable?

Does the media refer more to ZVRA or IRON?

Do analysts recommend ZVRA or IRON?

Which has more risk and volatility, ZVRA or IRON?

Do insiders & institutionals hold more shares of ZVRA or IRON?

Summary

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Which has better earnings & valuation, ZVRA or RARE?

Is ZVRA or RARE more profitable?

Does the media refer more to ZVRA or RARE?

Do analysts recommend ZVRA or RARE?

Which has more risk and volatility, ZVRA or RARE?

Do insiders & institutionals hold more shares of ZVRA or RARE?

Summary

How does Zevra Therapeutics compare to Vera Therapeutics?

Which has more volatility and risk, VERA or ZVRA?

Which has stronger earnings & valuation, VERA or ZVRA?

Do analysts rate VERA or ZVRA?

Do institutionals & insiders believe in VERA or ZVRA?

Is VERA or ZVRA more profitable?

Does the media prefer VERA or ZVRA?

Summary

How does Zevra Therapeutics compare to Immunome?

Which has more volatility & risk, ZVRA or IMNM?

Which has preferable earnings and valuation, ZVRA or IMNM?

Do analysts rate ZVRA or IMNM?

Do insiders and institutionals believe in ZVRA or IMNM?

Is ZVRA or IMNM more profitable?

Does the media prefer ZVRA or IMNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools